Use of the conditional marketing authorization pathway for oncology medicines in Europe

Conditional marketing authorization (CMA) in the European Union (EU) is an early access pathway for medicines that show promising therapeutic effects, but for which comprehensive data are not available. Using a mixed quantitative-qualitative research design, we evaluated how CMA has been used in mar...

Full description

Bibliographic Details

Published in:	Clinical pharmacology and therapeutics Vol. 98; no. 5; p. 534
Main Authors:	Hoekman, J, Boon, W P C, Bouvy, J C, Ebbers, H C, de Jong, J P, De Bruin, M L
Format:	Journal Article
Language:	English
Published:	United States 01.11.2015
Subjects:	Antineoplastic Agents - therapeutic use Cohort Studies Drug Approval - legislation & jurisprudence Drug Approval - methods Europe European Union Humans Marketing - legislation & jurisprudence Marketing - methods Europe
ISSN:	1532-6535, 1532-6535
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!